Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsfailuretransplantationcongestiveangina
  Phrases that lowered it: druguse ofhistoryadministrationthe trial
• Sponsor's past termination rate: 1.8% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 61 (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.4% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 73845 (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 8.1% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation NCT03031470 · started 2015 · scored riskier than 86% of active trials terminated
• TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion NCT01564095 · started 2011 · scored riskier than 56% of active trials terminated
• Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction NCT01453218 · started 2011 · scored riskier than 59% of active trials completed
• REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy NCT02115113 · started 2014 · scored riskier than 64% of active trials completed
• Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients NCT00622869 · started 2008 · scored riskier than 55% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.